
Treatment patterns in moderate-to-severe plaque psoriasis : results from a Belgian cross-sectional study (DISCOVER)
- Author
- Julien Lambert, Pierre-Dominique Ghislain, Jo Lambert (UGent) , Bénédicte Cauwe and Maria Van den Enden
- Organization
- Abstract
- Purpose: The present study aimed to evaluate current treatment patterns and achievement of treatment goals in Belgian patients with moderate-to-severe plaque psoriasis. Materials and methods: This cross-sectional observational study (DISCOVER) was conducted in 2011 - 2012 in Belgian dermatology centers. Patient data were collected during a single visit and included information on psoriasis management and severity (PASI and DLQI). Treatment success was defined according to the current European consensus treatment goal algorithm. Results: Of the 556 patients included in the study, 38.1% reported no current treatment or only topicals, 34.2% were being treated with traditional systemics and/or phototherapy, and 29.5% with biologics. Methotrexate (11.7%) was the most commonly prescribed traditional systemic and adalimumab (14.2%) was the most commonly prescribed biologic agent at the time of the study. The percentage of patients achieving treatment goals was significantly higher in biologic-treated patients (73.1%) compared to those using traditional systemics (50.6%), phototherapy (41.1%), or no treatment/only topicals (20.9%; p<.001). Conclusions: Nearly 40% of Belgian patients with moderate-to-severe psoriasis in the DISCOVER study were undertreated despite the severity of their disease. Undertreatment of psoriasis remains a problem in Belgium and more effective educational strategies are needed to ensure the best treatment outcome for these patients.
- Keywords
- Epidemiological survey, real-life setting, psoriasis treatment, treatment goals, TREATMENT GOALS, TREATMENT DISSATISFACTION, CLINICAL-TRIALS, PREVALENCE, ADALIMUMAB, CARE, METHOTREXATE, CYCLOSPORINE, SATISFACTION, GUIDELINES
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 1.11 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8525094
- MLA
- Lambert, Julien, et al. “Treatment Patterns in Moderate-to-Severe Plaque Psoriasis : Results from a Belgian Cross-Sectional Study (DISCOVER).” JOURNAL OF DERMATOLOGICAL TREATMENT, vol. 28, no. 5, 2017, pp. 394–400, doi:10.1080/09546634.2016.1255304.
- APA
- Lambert, J., Ghislain, P.-D., Lambert, J., Cauwe, B., & Van den Enden, M. (2017). Treatment patterns in moderate-to-severe plaque psoriasis : results from a Belgian cross-sectional study (DISCOVER). JOURNAL OF DERMATOLOGICAL TREATMENT, 28(5), 394–400. https://doi.org/10.1080/09546634.2016.1255304
- Chicago author-date
- Lambert, Julien, Pierre-Dominique Ghislain, Jo Lambert, Bénédicte Cauwe, and Maria Van den Enden. 2017. “Treatment Patterns in Moderate-to-Severe Plaque Psoriasis : Results from a Belgian Cross-Sectional Study (DISCOVER).” JOURNAL OF DERMATOLOGICAL TREATMENT 28 (5): 394–400. https://doi.org/10.1080/09546634.2016.1255304.
- Chicago author-date (all authors)
- Lambert, Julien, Pierre-Dominique Ghislain, Jo Lambert, Bénédicte Cauwe, and Maria Van den Enden. 2017. “Treatment Patterns in Moderate-to-Severe Plaque Psoriasis : Results from a Belgian Cross-Sectional Study (DISCOVER).” JOURNAL OF DERMATOLOGICAL TREATMENT 28 (5): 394–400. doi:10.1080/09546634.2016.1255304.
- Vancouver
- 1.Lambert J, Ghislain P-D, Lambert J, Cauwe B, Van den Enden M. Treatment patterns in moderate-to-severe plaque psoriasis : results from a Belgian cross-sectional study (DISCOVER). JOURNAL OF DERMATOLOGICAL TREATMENT. 2017;28(5):394–400.
- IEEE
- [1]J. Lambert, P.-D. Ghislain, J. Lambert, B. Cauwe, and M. Van den Enden, “Treatment patterns in moderate-to-severe plaque psoriasis : results from a Belgian cross-sectional study (DISCOVER),” JOURNAL OF DERMATOLOGICAL TREATMENT, vol. 28, no. 5, pp. 394–400, 2017.
@article{8525094, abstract = {{Purpose: The present study aimed to evaluate current treatment patterns and achievement of treatment goals in Belgian patients with moderate-to-severe plaque psoriasis. Materials and methods: This cross-sectional observational study (DISCOVER) was conducted in 2011 - 2012 in Belgian dermatology centers. Patient data were collected during a single visit and included information on psoriasis management and severity (PASI and DLQI). Treatment success was defined according to the current European consensus treatment goal algorithm. Results: Of the 556 patients included in the study, 38.1% reported no current treatment or only topicals, 34.2% were being treated with traditional systemics and/or phototherapy, and 29.5% with biologics. Methotrexate (11.7%) was the most commonly prescribed traditional systemic and adalimumab (14.2%) was the most commonly prescribed biologic agent at the time of the study. The percentage of patients achieving treatment goals was significantly higher in biologic-treated patients (73.1%) compared to those using traditional systemics (50.6%), phototherapy (41.1%), or no treatment/only topicals (20.9%; p<.001). Conclusions: Nearly 40% of Belgian patients with moderate-to-severe psoriasis in the DISCOVER study were undertreated despite the severity of their disease. Undertreatment of psoriasis remains a problem in Belgium and more effective educational strategies are needed to ensure the best treatment outcome for these patients.}}, author = {{Lambert, Julien and Ghislain, Pierre-Dominique and Lambert, Jo and Cauwe, Bénédicte and Van den Enden, Maria}}, issn = {{0954-6634}}, journal = {{JOURNAL OF DERMATOLOGICAL TREATMENT}}, keywords = {{Epidemiological survey,real-life setting,psoriasis treatment,treatment goals,TREATMENT GOALS,TREATMENT DISSATISFACTION,CLINICAL-TRIALS,PREVALENCE,ADALIMUMAB,CARE,METHOTREXATE,CYCLOSPORINE,SATISFACTION,GUIDELINES}}, language = {{eng}}, number = {{5}}, pages = {{394--400}}, title = {{Treatment patterns in moderate-to-severe plaque psoriasis : results from a Belgian cross-sectional study (DISCOVER)}}, url = {{http://doi.org/10.1080/09546634.2016.1255304}}, volume = {{28}}, year = {{2017}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: